Pricing Log in Create free account
Saturday 17 October 2026 Export PODD’s income statement to Excel — free account

Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insulet Corporation (PODD) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Sep 21, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Sep 14, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
8-K Sep 3, 2026 5.02 Departure or appointment of directors or officers
10-Q Jun 30, 2026 P1I2: 6 added · 2 removed · 28 modified
P2I1A: no comparison — incorporated by reference
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 24, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 26, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 20, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 29, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 12, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 27, 2026 5.02 Departure or appointment of directors or officers
8-K/A Dec 15, 2025 4.01 Change in the certifying accountant; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 8 added · 25 removed · 56 modified
1A: 10 added · 47 removed · 75 modified
7: 22 added · 22 removed · 42 modified
8-K Feb 18, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 29, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Dec 15, 2025 4.01 Change in the certifying accountant; 9.01 Financial statements and exhibits Auditor change
8-K Dec 11, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 21, 2025 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 11, 2025 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.